14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
GRAL vs DGX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Quest Diagnostics Inc. (DGX) is the stronger overall head-to-head candidate over GRAIL, Inc. (GRAL) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GRAL carries a Unified Composite Score of 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin), whereas DGX carries 41.1/100 (SELL) at $262.21 (21.9x Forward P/E, 14.9% operating margin).
Composite vs. Pillar Nuance: While GRAL currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. DGX 41.1/100 SELL), DGX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (14.9% vs. -332.0% operating margin) and revenue trajectory (+10.0% vs. +3.7% YoY).
Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile DGX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 71.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Diagnostics & Research value chain with $28.6B market capitalization and 14.9% operating margin.
OpEx & R&D Reinvestment18.3% of Rev ($2.17B)
90D Engineering Disclosures0 Published
Investor FAQ GRAL vs DGX Key Questions & Quantitative Answers
As of Nov 16, 2026, Quest Diagnostics Inc. (DGX) is the stronger overall head-to-head candidate over GRAIL, Inc. (GRAL) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GRAL carries a Unified Composite Score of 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin), whereas DGX carries 41.1/100 (SELL) at $262.21 (21.9x Forward P/E, 14.9% operating margin). Composite vs. Pillar Nuance: While GRAL currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. DGX 41.1/100 SELL), DGX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (14.9% vs. -332.0% operating margin) and revenue trajectory (+10.0% vs. +3.7% YoY). Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile DGX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 71.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DGX leads the Growth & Scale pillar: GRAL posts +3.7% YoY revenue growth and +0.0% YoY earnings growth on $167M TTM revenue (46.7% gross margin, -332.0% operating margin), compared with DGX at +10.0% YoY revenue growth and +28.7% YoY earnings growth on $11.8B TTM revenue (33.2% gross margin, 14.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), GRAL cumulative revenue shifted +66.7% while DGX shifted +46.6%. In operating R&D and SG&A reinvestment, GRAL deploys N/A (0 90-day corporate R&D disclosures) versus 18.3% of Rev ($2.17B) (0 disclosures) for DGX.
GRAL screens cheaper on headline valuation multiples. GRAL trades at 1.1x Forward P/E, 1.1x Trailing P/E, N/M PEG, and 31.6x EV/Revenue (unreported FCF margin), whereas DGX trades at 21.9x Forward P/E, 25.9x Trailing P/E, 1.68x PEG, and 2.9x EV/Revenue (11.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GRAL (-17.3% ROE) versus DGX (15.3% ROE) capital efficiency.
In options market volatility and institutional positioning, GRAL carries 93.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), a 0.81x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.09β · 99% Vol realized risk). By comparison, DGX carries 29.3% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.06β · 19% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.